8-K: BioLargo Secures $10M Equity Line with ClearThink Capital

BioLargo, Inc. has entered into a purchase agreement with ClearThink Capital Partners, LLC for up to $10 million in common stock over 36 months, enhancing its capital access.

Summary

• BioLargo, Inc. (BLGO) signed a Purchase Agreement and a Registration Rights Agreement with ClearThink Capital Partners, LLC on March 20, 2026.
• ClearThink Capital has committed to purchase up to $10,000,000 of BioLargo's common stock over a 36-month period, at BioLargo's discretion.
• BioLargo has the right, but not the obligation, to sell shares, and ClearThink is obligated to purchase them, subject to certain conditions.
• The purchase price for shares will be based on the average of the two lowest daily closing prices during the eight trading days preceding a purchase notice.
• As consideration for the commitment, BioLargo issued 500,000 shares of its common stock to ClearThink Capital upon execution of the agreement, for which BioLargo will not receive cash proceeds.
• BioLargo is required to file an S-1 Registration Statement within 30 days of March 20, 2026, to cover the resale of these shares by ClearThink.
• The company expects to use any proceeds from these sales for working capital and general corporate purposes.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it secures a significant capital commitment for BioLargo, providing financial flexibility. However, the potential for dilution from future stock sales and the immediate issuance of commitment shares temper the overall sentiment.

Positives

• Secured a commitment for up to $10 million in equity financing, providing a flexible source of capital for the company's operations.
• BioLargo retains control over the timing and amount of stock sales, allowing it to manage capital inflows strategically.
• ClearThink Capital is prohibited from engaging in short sales or hedging transactions that establish a net short position in BioLargo's common stock during the agreement term, which could help stabilize the stock price.
• BioLargo has the right to terminate the Purchase Agreement at any time with one business day's notice, at no cost or penalty.

Negatives

• The issuance of 500,000 Commitment Shares to ClearThink Capital as a fee results in immediate dilution for existing shareholders without any cash proceeds to the company.
• Future sales of up to $10 million in common stock will cause further dilution to existing shareholders as new shares are issued.
• The purchase price mechanism, based on the average of the two lowest daily closing prices during the eight trading days preceding a purchase notice, could result in sales at a discount to prevailing market prices, potentially increasing dilution.

Risks

• The effectiveness of the capital raise is contingent on the SEC declaring the S-1 Registration Statement effective, and any delays or stop orders could hinder the company's ability to access funds.
• There is potential for significant dilution to existing shareholders as shares are sold to ClearThink Capital over the 36-month period.
• The company acknowledges a weakness in internal controls, as disclosed in its SEC Documents, which could pose operational and financial reporting risks.
• Events of default, such as the lapse of the registration statement, suspension of trading, or delisting from OTCQX, could prevent the company from drawing on the commitment.
• Failure to comply with publicity requirements (Section 12(i) of the Purchase Agreement) constitutes a Material Adverse Effect, potentially leading to adverse consequences for the company.

Future Outlook

BioLargo expects to use any net proceeds from the sales of common stock to ClearThink Capital for working capital and general corporate purposes. The company will control the timing and amount of sales, taking into consideration market conditions, the trading price of its common stock, and determinations as to the appropriate sources of funding for the company and its operations.

Management Comments

• We expect that any proceeds we receive from such sales to Clearthink will be used for working capital and general corporate purposes.

Industry Context

StockSavvy.ai notes that equity lines of credit, while providing flexible access to capital, are common for smaller public companies, particularly those on OTC markets, seeking to fund operations without the immediate pressure of traditional debt or larger, more structured equity offerings. This type of financing can be attractive for companies with fluctuating capital needs or those in growth phases.

Comparison to Industry Standards

• StockSavvy.ai observes that the terms of this equity line, including the issuance of commitment shares and the pricing mechanism based on the lowest daily closing prices, are generally consistent with 'at-the-market' or 'equity line' facilities offered by institutional investors to smaller-cap companies.
• While providing capital flexibility, these structures often involve significant potential for dilution compared to a fixed-price offering.
• Specific comparable companies or projects are not detailed in the filing, but similar arrangements have been seen with firms like Lincoln Park Capital or Aspire Capital, which specialize in providing such financing to micro-cap and small-cap public companies.

Corporate Governance

Related Party Transactions

• Dennis Calvert (CEO of BioLargo) invested $120,000 and $21,000 in Clyra Medical Technologies 2024 promissory notes on October 22, 2024.
• Dennis Calvert (CEO of BioLargo) invested $100,000 in Clyra Medical Technologies 2026 Guaranteed Note Offering on February 16, 2026.
• Steven Harrison (CEO of Clyra Medical Technologies) invested $25,000 in Clyra Medical Technologies 2025 Guaranteed Note offering on June 2, 2025.
• Steven Harrison (CEO of Clyra Medical Technologies) invested $50,000 in Clyra Medical Technologies 2026 Guaranteed Note offering on February 19, 2026.
• These transactions were on the same terms and conditions as other investors in the respective offerings.

Stakeholder Impact

• Shareholders face potential dilution from the immediate issuance of 500,000 commitment shares and future sales of up to $10 million in common stock. The pricing mechanism based on lowest daily closing prices could exacerbate dilution.
• Company operations gain access to a flexible capital source for working capital and general corporate purposes, which can support ongoing initiatives and growth strategies.
• Creditors may view the equity financing as a positive development, potentially improving the company's balance sheet and liquidity, thereby reducing credit risk.

Next Steps

• BioLargo must file an S-1 Registration Statement with the SEC within 30 days of March 20, 2026, to register the resale of the Purchase Shares and Commitment Shares.
• The Registration Statement must be declared effective by the SEC for the sales to ClearThink Capital to commence.
• BioLargo will, at its discretion, issue purchase notices to ClearThink Capital to sell common stock over the 36-month term, subject to market conditions and other factors.

Key Dates

Recommendation

The equity line provides BioLargo with a flexible capital source, which is a positive for liquidity and operational funding. However, the terms, including the issuance of commitment shares and the pricing mechanism based on the lowest daily closing prices, introduce significant potential for dilution for existing shareholders. While the company controls the timing of sales, the structure suggests a need for capital that could weigh on the stock price. Given the balance of improved capital access against potential dilution, a 'hold' recommendation is appropriate for seasoned investors to observe how the company utilizes this facility and manages its capital structure.

Keywords

BioLargo, BLGO, ClearThink Capital, equity line, common stock, capital raise, dilution, SEC filing, 8-K, registration rights, purchase agreement, working capital, corporate finance, OTCQX